On February 14th, 2018 a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC).
On February 14th, 2018 a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM) reviewed new drug application (NDA) 209257 for Charleston Laboratories’ novel pain drug, Hydexor. Hydexor is a fixed-dose combination oral tablet containing hydrocodone, acetaminophen, and promethazine for the treatment of acute pain in those suffering from enough pain to require an opioid analgesic, while preventing opioid-induced nausea and vomiting (OINV).
Many patients experience OINV when prescribed opioid products for the management of acute pain. Promethazine, one of the active drug substances in Hydexor, provides antiemetic benefits, mitigating OINV. If approved, Hydexor would be the first opioid product to include an antiemetic agent in the formulation.
The sponsor presented data from their clinical program, which included three phase 1 bioavailability studies and two phase 3 studies. Upon completion of the presentation segment of the meeting, panel members expressed concern over the side effects of Hydexor, which included participants feeling dizzy, drowsy, and confused. Given that these side effects were the most common adverse events reported in the sponsor’s clinical program, panel members questioned the prophylactic use of promethazine for OINV. Panelists also expressed concern over the sponsor’s approach to marketing only one strength of Hydexor, prompting the discussion of whether single strength is useful for certain patient needs.
When asked by the FDA if Hydexor should be approved for marketing in the US, panel members voted against approval, 2 (yes) and 19 (no).
ISS has almost two decades of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComms per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact firstname.lastname@example.org
Download ISS' Essential Guide to Preparing for a Meeting at the FDA White Oak Campus
Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more
FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more
One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more
US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us